Literature DB >> 8228223

Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions.

D M Calderhead1, J E Buhlmann, A J van den Eertwegh, E Claassen, R J Noelle, H P Fell.   

Abstract

A cDNA library was prepared from the murine Th cell line Th2 D.10 and used to clone the murine homologue of Ox40 by polymerase chain reaction. Comparison of the mouse sequence with the rat revealed greater than 90% homology between the two sequences at both the DNA and protein level. Northern blot analysis found that, as in the rat, Ox40 expression appears to be restricted to activated T cells. A chimeric receptor globulin was prepared to include the mouse Ox40 extracellular domain coupled to the hinge-CH2-CH3 domains of human IgG1 (Ox40-Ig). This soluble form of the molecular was then used to identify cells bearing a ligand for Ox40. FACS analysis revealed that Ox40-Ig bound to a subset of peritoneal B cells as well as to a fraction of LPS-activated splenic B cells. Immunostaining of spleen sections using an Ag-specific conjugate and Ox40-Ig found a significant proportion of antibody-forming cells co-stained with Ox40-Ig. Immunoprecipitation of cell-surface radiolabeled peritoneal B cells suggests a specific interaction with a protein of 70 kDa.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8228223

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

1.  Essential role of OX40L on B cells in persistent alloantibody production following repeated alloimmunizations.

Authors:  Hiroshi Kato; Hidefumi Kojima; Naoto Ishii; Hidenori Hase; Yutaka Imai; Takashi Fujibayashi; Kazuo Sugamura; Testuji Kobata
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

2.  OX40 is a potent immune-stimulating target in late-stage cancer patients.

Authors:  Brendan D Curti; Magdalena Kovacsovics-Bankowski; Nicholas Morris; Edwin Walker; Lana Chisholm; Kevin Floyd; Joshua Walker; Iliana Gonzalez; Tanisha Meeuwsen; Bernard A Fox; Tarsem Moudgil; William Miller; Daniel Haley; Todd Coffey; Brenda Fisher; Laurie Delanty-Miller; Nicole Rymarchyk; Tracy Kelly; Todd Crocenzi; Eric Bernstein; Rachel Sanborn; Walter J Urba; Andrew D Weinberg
Journal:  Cancer Res       Date:  2013-10-31       Impact factor: 12.701

Review 3.  Regulation of apoptosis in immune cells.

Authors:  J D Mountz; T Zhou; J Wu; W Wang; X Su; J Cheng
Journal:  J Clin Immunol       Date:  1995-01       Impact factor: 8.317

4.  OX40 signaling renders adult T-cell leukemia cells resistant to Fas-induced apoptosis.

Authors:  Akane Kunitomi; Toshiyuki Hori; Michiyuki Maeda; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2002-10       Impact factor: 2.490

5.  Herpes virus entry mediator synergizes with Toll-like receptor mediated neutrophil inflammatory responses.

Authors:  Philipp Haselmayer; Stefan Tenzer; Byoung S Kwon; Gundram Jung; Hansjörg Schild; Markus P Radsak
Journal:  Immunology       Date:  2006-11       Impact factor: 7.397

Review 6.  Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.

Authors:  Rachel E O'Neill; Xuefang Cao
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

Review 7.  Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).

Authors:  Bruce R Blazar; William J Murphy
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

8.  OX40 costimulation turns off Foxp3+ Tregs.

Authors:  Minh Diem Vu; Xiang Xiao; Wenda Gao; Nicolas Degauque; Ming Chen; Alexander Kroemer; Nigel Killeen; Naoto Ishii; Xian Chang Li
Journal:  Blood       Date:  2007-06-15       Impact factor: 22.113

Review 9.  Function of tumor necrosis factor receptor family members on regulatory T-cells.

Authors:  Robert H Arch
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

10.  Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.

Authors:  David J Messenheimer; Shawn M Jensen; Michael E Afentoulis; Keith W Wegmann; Zipei Feng; David J Friedman; Michael J Gough; Walter J Urba; Bernard A Fox
Journal:  Clin Cancer Res       Date:  2017-08-28       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.